Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherPROSTAGLANDINS, LEUKOTRIENES AND OTHER EICOSANOIDS

Variabilin: A Dual Inhibitor of Human Secretory and Cytosolic Phospholipase A2 With Anti-inflammatory Activity

V. Escrig, A. Ubeda, M. L. Ferrandiz, J. Darias, J. M. Sanchez, M. J. Alcaraz and M. Paya
Journal of Pharmacology and Experimental Therapeutics July 1997, 282 (1) 123-131;
V. Escrig
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Ubeda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. L. Ferrandiz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Darias
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. M. Sanchez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. J. Alcaraz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Paya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The marine product variabilin was identified as a novel inhibitor of phospholipase A2 (PLA2), which exhibited IC50 values of 6.9 μM and 7.9 μM for human synovial secretory PLA2 and U937 cells cytosolic PLA2activities, respectively. This compound was less potent on bee venom or zymosan-injected rat air pouch enzymes and failed to affect Naja naja venom PLA2. The production of leukotriene B4 by human neutrophils stimulated with calcium ionophore A23187 was also inhibited by variabilin, which was without effect on 5-lipoxygenase, cyclo-oxygenase 1 and cyclo-oxygenase 2 activities in cell-free assays. Other functions of human neutrophils, such as degranulation and superoxide generation, were also significantly reduced in vitro. Variabilin administered topically suppressed the mouse ear edema induced by 12-O-tetradecanoylphorbol 13-acetate, whereas the ear edema induced by arachidonic acid was unaffected; this suggests an action previous to arachidonic acid metabolism. This compound administered p.o. at 30 mg/kg and 45 mg/kg significantly inhibited mouse paw edema induced by carrageenan and, at 0.01 to 1.0 μmol/pouch in the mouse air pouch injected with zymosan, exerted a marked inhibition on PGE2 and leukotriene B4 levels in exudates (ID50 values of approximately 0.028–0.029 μmol/pouch), without affecting cell migration. Our results indicate that variabilin is an inhibitor of human secretory and cytosolic PLA2activities that controls eicosanoid production in vitro andin vivo, inhibits neutrophil degranulation and superoxide generation in vitro and shows anti-inflammatory activity after topical or p.o. administration to mice.

Footnotes

  • Send reprint requests to: Dr. M. Payá, Department of Pharmacology. University of Valencia, Faculty of Pharmacy. Avda. Vicent Andrés Estellés s/n, 46100 Burjassot, Valencia, Spain.

  • ↵1 This work was supported by grant SAF95-1046 from CICYT, Spanish Ministerio de Educación y Ciencia.

  • Abbreviations:
    PLA2
    phospholipase A2
    sPLA2
    secretory phospholipase A2
    cPLA2
    cytosolic phospholipase A2
    LTB4
    leukotriene B4
    LTC4
    leukotriene C4
    TPA
    12-O-tetradecanoylphorbol 13-acetate
    PTK
    palmityl trifluoromethyl ketone
    BSA
    bovine serum albumin
    PBS
    phosphate-buffered saline
    LDH
    lactate dehydrogenase
    FMLP
    formyl-l-methionil-l-leucyl-l-phenylalanine
    PAF
    platelet-activating factor
    IC50
    inhibitory concentration 50%
    ID50
    inhibitory dose 50%
    • Received November 12, 1996.
    • Accepted March 17, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 282, Issue 1
1 Jul 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Variabilin: A Dual Inhibitor of Human Secretory and Cytosolic Phospholipase A2 With Anti-inflammatory Activity
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherPROSTAGLANDINS, LEUKOTRIENES AND OTHER EICOSANOIDS

Variabilin: A Dual Inhibitor of Human Secretory and Cytosolic Phospholipase A2 With Anti-inflammatory Activity

V. Escrig, A. Ubeda, M. L. Ferrandiz, J. Darias, J. M. Sanchez, M. J. Alcaraz and M. Paya
Journal of Pharmacology and Experimental Therapeutics July 1, 1997, 282 (1) 123-131;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherPROSTAGLANDINS, LEUKOTRIENES AND OTHER EICOSANOIDS

Variabilin: A Dual Inhibitor of Human Secretory and Cytosolic Phospholipase A2 With Anti-inflammatory Activity

V. Escrig, A. Ubeda, M. L. Ferrandiz, J. Darias, J. M. Sanchez, M. J. Alcaraz and M. Paya
Journal of Pharmacology and Experimental Therapeutics July 1, 1997, 282 (1) 123-131;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Biosynthesis of Sulfidopeptide Leukotrienes Via the Transfer of Leukotriene A4 from Polymorphonuclear Cells to Bovine Retinal Pericytes
  • The Preclinical Pharmacological Profile of the Potent and Selective Leukotriene B4 Antagonist CP-195543
  • Tyrosine Phosphatase-Dependent/Tyrosine Kinase-Independent Induction of Nuclear Factor-κB by Tumor Necrosis Factor-α: Effects on Prostaglandin Endoperoxide Synthase-2 mRNA Accumulation
Show more PROSTAGLANDINS, LEUKOTRIENES AND OTHER EICOSANOIDS

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics